First-Ever treatment tested for mysterious immune deficiency
NCT ID NCT04097561
Summary
This study is testing whether a drug called belimumab is safe for people with idiopathic CD4 lymphopenia (ICL), a rare condition where the body has too few infection-fighting white blood cells. Twenty adults with ICL will receive belimumab through an IV over six months and be closely monitored. The goal is to see if this drug, already used for lupus, can be safely given to people with ICL to potentially help control their condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 LYMPHOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.